Tipharmlor Dosage

Was this medicine useful for you?
sponsored

Dosage of Tipharmlor in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Usual Adult Dose of Tipharmlor for Hypertension:

Initial dose: 5 mg orally once a day

Maintenance dose: 5 to 10 mg orally once a day

Maximum dose: 10 mg/day

Comments:

-Patients who are small or fragile may be started on 2.5 mg orally once a day.

-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.

Use:

-Alone or in combination with other antihypertensive agents to treat hypertension

Usual Adult Dose of Tipharmlor for Angina Pectoris:

Maintenance dose: 5 to 10 mg orally once a day

Maximum dose: 10 mg/day

Comments:

-In clinical studies, most patients with angina or coronary artery disease (CAD) required 10 mg orally once a day.

-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.

Uses:

-Alone or in combination with other antianginal agents for the symptomatic treatment of chronic stable angina

-Alone or in combination with other antianginal agents for the treatment of confirmed/suspected vasospastic angina

-To reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%

Usual Adult Dose of Tipharmlor for Coronary Artery Disease:

Maintenance dose: 5 to 10 mg orally once a day

Maximum dose: 10 mg/day

Comments:

-In clinical studies, most patients with angina or coronary artery disease (CAD) required 10 mg orally once a day.

-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.

Uses:

-Alone or in combination with other antianginal agents for the symptomatic treatment of chronic stable angina

-Alone or in combination with other antianginal agents for the treatment of confirmed/suspected vasospastic angina

-To reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%

Usual Geriatric Dose of Tipharmlor for Hypertension:

Initial dose: 2.5 mg orally once a day

Maintenance dose: 2.5 to 10 mg orally once a day

Maximum dose: 10 mg/day

Comment:

-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.

Use:

-Alone or in combination with other antihypertensive agents to treat hypertension

Usual Geriatric Dose of Tipharmlor for Angina Pectoris:

Initial dose: 5 mg orally once a day

Maintenance dose: 5 to 10 mg orally once a day

Maximum dose: 10 mg/day

Comments:

-In clinical studies, most patients with angina or coronary artery disease (CAD) required 10 mg orally once a day.

-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.

Uses:

-Alone or in combination with other antianginal agents for the symptomatic treatment of chronic stable angina

-Alone or in combination with other antianginal agents for the treatment of confirmed/suspected vasospastic angina

-To reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%

Usual Pediatric Dose of Tipharmlor for Hypertension:

6 to 17 years:

-Maintenance dose: 2.5 to 5 mg orally once a day

-Maximum dose: 5 mg/day

Comments:

-Doses higher than 5 mg have not been studied in pediatric patients.

The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.

Use:

-Alone or in combination with other antihypertensive agents to treat hypertension

What other drugs will affect Tipharmlor?

Tell your doctor about all your current medicines and any you start or stop using, especially:

This list is not complete. Other drugs may interact with Tipharmlor, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Tipharmlor interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Tipharmlor, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Tipharmlor has been safely administered with thiazide diuretics, alpha blockers, beta-blockers, ACE inhibitors, long-acting nitrates, sublingual nitroglycerine, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.

In vitro data from studies with human plasma indicate that Tipharmlor has no effect on protein binding of the drugs tested (digoxin, phenytoin, warfarin, or indomethacin).

Simvastatin: Co-administration of multiple doses of 10 mg Tipharmlor with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on Tipharmlor to 20 mg daily.

Grapefruit Juice: Co-administration of 240 mL grapefruit juice with a single oral dose of 10 mg Tipharmlor in 20 healthy volunteers had no significant effect on the pharmacokinetics of Tipharmlor. The study did not allow examination of the effect of genetic polymorphism in CYP3A4, the primary enzyme responsible for metabolism of Tipharmlor; therefore, administration of Tipharmlor with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.

CYP3A4 Inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg Tipharmlor in elderly hypertensive patients (69 to 87 years of age) resulted in a 57% increase in Tipharmlor systemic exposure. Co-administration of erythromycin in healthy volunteers (18 to 43 years of age) did not significantly change Tipharmlor systemic exposure (22% increase in area under the concentration versus time curve [AUC]). Although the clinical relevance of these findings is uncertain, pharmacokinetic variations may be more pronounced in the elderly.

Strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of Tipharmlor to a greater extent than diltiazem. Tipharmlor should be used with caution when administered with CYP3A4 inhibitors.

Clarithromycin: Clarithromycin is an inhibitor of CYP3A4. There is an increased risk of hypotension in patients receiving clarithromycin with Tipharmlor. Close observation of patients is recommended when Tipharmlor is co-administered with clarithromycin.

CYP3A4 Inducers: There is no data available regarding the effect of CYP3A4 inducers on Tipharmlor. Concomitant use of CYP3A4 inducers (e.g., rifampicin, hypericum perforatum) may decrease the plasma concentrations of Tipharmlor. Tipharmlor should be used with caution when administered with CYP3A4 inducers.

In the following studies, there were no significant changes in the pharmacokinetics of either Tipharmlor or another drug within the study, when co-administered.

Special Studies: Effect of Other Agents on Tipharmlor: Cimetidine: Co-administration of Tipharmlor with cimetidine did not alter the pharmacokinetics of Tipharmlor.

Aluminum/Magnesium (Antacid): Co-administration of aluminum/magnesium (antacid) with a single dose of Tipharmlor had no significant effect on the pharmacokinetics of Tipharmlor.

Sildenafil: A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of Tipharmlor. When Tipharmlor and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.

Special Studies: Effect of Tipharmlor on Other Agents: Atorvastatin: Co-administration of multiple 10 mg doses of Tipharmlor with 80 mg atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.

Digoxin: Co-administration of Tipharmlor with digoxin did not change serum digoxin levels or digoxin renal clearance in healthy volunteers.

Ethanol (Alcohol): Single and multiple 10 mg doses of Tipharmlor had no significant effect on the pharmacokinetics of ethanol.

Warfarin: Co-administration of Tipharmlor with warfarin did not change the warfarin prothrombin response time.

Cyclosporin: No drug interaction studies have been conducted with cyclosporin and Tipharmlor in healthy volunteers or other populations, with the exception of renal transplant patients. Various studies in renal transplant patients report that co-administration of Tipharmlor with cyclosporin affects the trough concentrations of cyclosporin, from no change up to an average increase of 40%. Consideration should be given for monitoring cyclosporin levels in renal transplant patients on Tipharmlor.

Tacrolimus: There is a risk of increased tacrolimus blood levels when co-administered with Tipharmlor. In order to avoid toxicity of tacrolimus, administration of Tipharmlor in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.

Drug/Laboratory Test Interactions: None known.


sponsored

References

  1. MeSH. "Antihypertensive Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
  2. European Chemicals Agency - ECHA. "3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
  3. PubMed Health. "Norvasc: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Tipharmlor are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tipharmlor. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 26 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved